PMID- 32607924
OWN - NLM
STAT- MEDLINE
DCOM- 20211216
LR  - 20211216
IS  - 1559-0267 (Electronic)
IS  - 1080-0549 (Linking)
VI  - 61
IP  - 2
DP  - 2021 Oct
TI  - Treatments for Childhood Atopic Dermatitis: an Update on Emerging Therapies.
PG  - 114-127
LID - 10.1007/s12016-020-08799-1 [doi]
AB  - Atopic dermatitis (AD) is generally considered a T helper type 2-dominated 
      disease. Pediatric AD is usually less severe than adult AD, but it may present as 
      moderate to severe lesions that are inadequately managed by current modalities 
      including emollients/moisturizers, topical corticosteroids (TCSs), topical 
      calcineurin inhibitors (TCIs), and even systemic immunosuppressants (such as 
      cyclosporine, azathioprine, methotrexate, and mycophenolate mofetil). In 
      addition, systemic immunosuppressants are often not recommended for childhood AD 
      by the current guidelines due to their toxicities. Therefore, there is still an 
      unmet need for a safe and effective long-term therapy for pediatric AD patients 
      whose disease is inadequately controlled or who are intolerant to current 
      treatments. The emerging therapeutics for AD focuses on intervening in the 
      inflammatory pathway by targeting specific cytokines/chemokines or their 
      receptors. Monoclonal antibodies against immunoglobulin E (IgE), interleukin 
      (IL)-4 receptor subunit alpha, IL-5, IL-13, IL-31 receptor subunit alpha, IL-33, and 
      thymic stromal lymphopoietin (TSLP) have been evaluated clinically for AD. 
      Encouraging results have been reported for many of the biologics, of which the 
      most exciting is dupilumab. Other emerging systemic therapies include small 
      molecules such as baricitinib, abrocitinib, upadacitinib, and tradipitant. 
      Several novel topical agents are under clinical investigation for the treatment 
      of AD, including topical phosphodiesterase 4 (PDE4) inhibitors, Janus kinase 
      (JAK) inhibitors, aryl hydrocarbon receptor (AhR) modulating agents, and 
      transient receptor potential vanilloid subfamily member 1 (TRPV1) antagonists. 
      Accompanied by thorough characterization of different phenotype and endotype 
      subsets, the application of precision medicine could provide new prospects for 
      the optimal treatment of AD.
CI  - (c) 2020. Springer Science+Business Media, LLC, part of Springer Nature.
FAU - Chu, Chia-Yu
AU  - Chu CY
AUID- ORCID: 0000-0002-9370-3279
AD  - Department of Dermatology, National Taiwan University Hospital and National 
      Taiwan University College of Medicine, No. 7, Chung-Shan South Road, Taipei, 
      10002, Taiwan. chiayu@ntu.edu.tw.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Rev Allergy Immunol
JT  - Clinical reviews in allergy & immunology
JID - 9504368
RN  - 0 (Dermatologic Agents)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Janus Kinase Inhibitors)
SB  - IM
MH  - Animals
MH  - Child
MH  - Dermatitis, Atopic/*drug therapy
MH  - Dermatologic Agents/therapeutic use
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Janus Kinase Inhibitors/therapeutic use
OTO - NOTNLM
OT  - Atopic dermatitis
OT  - Dupilumab
OT  - Eczema
OT  - Emerging treatment
OT  - Pruritus
EDAT- 2020/07/02 06:00
MHDA- 2021/12/17 06:00
CRDT- 2020/07/02 06:00
PHST- 2020/07/02 06:00 [pubmed]
PHST- 2021/12/17 06:00 [medline]
PHST- 2020/07/02 06:00 [entrez]
AID - 10.1007/s12016-020-08799-1 [pii]
AID - 10.1007/s12016-020-08799-1 [doi]
PST - ppublish
SO  - Clin Rev Allergy Immunol. 2021 Oct;61(2):114-127. doi: 
      10.1007/s12016-020-08799-1.